These include the cobas EGFR Mutation Test v2 from Roche that is a quantitative PCR (qPCR)-based test to detect EGFR exon 19 deletions or NP_005219.2:p.L858R substitution in metastatic NSCLC patients to identify eligibility for TKI treatment as well as for EGFR NP_005219.2:p.T790M resistance mutation [38]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.